Physician profile
Enrique Gorin
NPI 1518956572
$7,128.79
in general payments reported to CMS, 2019-2025
45 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $906 · 2021: $1,223 · 2022: $1,020 · 2023: $879 · 2024: $814 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $752.48 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $505.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $501.78 | 2019-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $483.27 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $451.25 | 2019-2023 | |
| Novo Nordisk INC | $392.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $353.80 | 2019-2025 | |
| Amarin Pharma, INC. | $343.44 | 2019-2022 | |
| Abbott Laboratories | $298.10 | 2019-2024 | Ensite, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.18 | 2019-2025 | Jardiance |
| Amgen INC. | $250.32 | 2020-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $233.42 | 2019-2025 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.21 | 2019-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $193.13 | 2020-2025 | Nexletol |
| Medtronic Vascular, INC. | $166.41 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Gorin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.